Working… Menu

Vinorelbine in Mesothelioma (VIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02139904
Recruitment Status : Unknown
Verified April 2019 by Wales Cancer Trials Unit.
Recruitment status was:  Active, not recruiting
First Posted : May 15, 2014
Last Update Posted : May 1, 2019
Pierre Fabre Laboratories
Information provided by (Responsible Party):
Wales Cancer Trials Unit

Brief Summary:

This study is for patients with malignant mesothelioma of the lung lining (called pleura) who have had previous chemotherapy with a platinum-based regimen whose disease has progressed. Malignant pleural mesothelioma (MPM) is an aggressive, frequently drug resistant, and incurable disease that is increasing in incidence in the UK and worldwide. All patients with MPM will relapse following first line chemotherapy and at present, there is no standard treatment available for patients in the second line setting. The vinca alkaloid chemotherapy drug vinorelbine has shown promising activity in a single arm UK trial. However to date, there has been no randomised evaluation of vinorelbine in mesothelioma in the second line setting. In addition, there have been no trials which have looked at underlying molecular changes in mesothelioma which may predict vinorelbine efficacy; This might allow vinorelbine to be used in patients only where there is a chance of benefit. Studies suggest that vinorelbine requires a gene called BRCA1 (shown to be absent in 38% of mesothelioma cases) in order to induce cell death in mesothelioma. The VIM trial aims to establish whether vinorelbine in patients with MPM helps them live longer and whether the BRCA1 gene is helpful in selecting patients most likely to benefit from treatment.

Patients will be randomised (1:2) to receive either active symptom control (ASC) (which is all supportive care deemed necessary for pain management excluding disease modifying treatment) or ASC with vinorelbine. Patients will continue vinorelbine treatment until evidence of disease progression (or unacceptable toxicity to the drug or patient withdrawal). If vinorelbine activity is demonstrated, we will use the results from this trial to inform the design of a future phase III trial.

Condition or disease Intervention/treatment Phase
Mesothelioma Drug: Vinorelbine Other: Active Symptom Control Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 157 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised Phase II Trial of Oral Vinorelbine as Second Line Therapy for Patients With Malignant Pleural Mesothelioma
Actual Study Start Date : March 1, 2016
Estimated Primary Completion Date : October 31, 2019
Estimated Study Completion Date : January 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Mesothelioma

Arm Intervention/treatment
Placebo Comparator: Active Symptom Control
Active symptom control includes palliative care and standard care methods used to manage symptoms
Other: Active Symptom Control
Active Comparator: Vinorelbine
Active symptom control (ASC) as per local practice plus vinorelbine administered at a dose of 60mg/m2 orally on day 1, day 8 and day 15 on a 3- weekly cycle, incrementing to 80mg/m2 weekly on a 3-weekly cycle in the absence of any significant toxicity for subsequent cycles. Patients will continue chemotherapy until evidence of radiological progression (or unacceptable toxicity or patient withdrawal).
Drug: Vinorelbine
Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
Other Name: Navelbine

Primary Outcome Measures :
  1. Overall Survival [ Time Frame: 2 years ]
    Anti-tumour activity of vinorelbine will be measured by overall survival, time from randomisation to death.

Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: 2 years ]
    Anti-tumour activity of vinorelbine will also be measured by progression free survival. We will document time from randomisation to any disease progression and/or death, defined according to strict RECIST v1.1. Lesions will be compared with baseline measurements to assess progression

  2. Number of serious adverse events reported [ Time Frame: 2 years ]
    The toxicity profile of oral vinorelbine in this setting will be used to assess safety. An independent data monitoring committee will convene and assess safety 6 months after the first patient has been randomised. If the trial is deemed safe to continue then safety will be assessed again approx every 6 months. Toxicity data will be assessed alongside serious adverse events.

  3. BRCA1 status in blood and tumour samples [ Time Frame: 2 years ]
    Tumour and blood samples will be collected for future translational research. BRCA1 expression as a putative predictor of vinorelbine sensitivity will be measured primarily in the samples.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Confirmed histological diagnosis of malignant pleural mesothelioma. The same block or 10 unstained slides should be available for translational research
  2. Prior treatment with first-line standard platinum doublet based chemotherapy only
  3. Evidence of disease progression according to CT scan
  4. Life expectancy ≥ 3 months
  5. ECOG performance status 0-2
  6. Men or women aged 18 years or over
  7. Willing to consent to provide blood and tissue for translational research
  8. Measurable lesions by modified RECIST
  9. Adequate organ function, including the following: Adequate bone marrow reserve: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, WBC >3 x 109/L, haemoglobin ≥ 100g/L, platelets ≥ 100 x 109/L; adequate liver function: Bilirubin <1.5 x ULN AST/ALT 1.5- 2.5 x ULN.
  10. Patients with reproductive potential (male or female), who are sexually active during the duration of the trial or the drug washout period, should be prepared to use two effective forms of contraception throughout their participation in the trial and for at least three months after the last dose of vinorelbine.
  11. Patients must provide informed consent prior to any study specific procedures.

Exclusion Criteria:

  1. Patients with a diagnosis of a second malignancy except prostate or cervical cancer in remission or patients with a diagnosis of basal cell carcinoma of the skin.
  2. Have received treatment with an agent that has not received regulatory approval, within 30 days of study entry.
  3. Are pregnant or breastfeeding.
  4. Uncontrolled CNS disease.
  5. Known contraindication or hypersensitivity to vinorelbine or other vinca alkaloids or to any of the constituents
  6. Any disease significantly affecting absorption
  7. Previous significant surgical resection of stomach or small bowel
  8. Yellow fever vaccine within 30 days of consent
  9. Previous vinca alkaloid chemotherapy
  10. Palliative radiotherapy within the RECIST area in the 4 weeks prior to baseline CT chest up until randomisation.
  11. Patients that are unable to swallow

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02139904

Layout table for location information
United Kingdom
Wales Cancer Trials Unit
Cardiff, United Kingdom, CF14 4YS
Sponsors and Collaborators
Wales Cancer Trials Unit
Pierre Fabre Laboratories
Layout table for investigator information
Study Chair: Dean Fennell, Professor University of Leicester
Layout table for additonal information
Responsible Party: Wales Cancer Trials Unit Identifier: NCT02139904    
Other Study ID Numbers: UNOLE 0329
First Posted: May 15, 2014    Key Record Dates
Last Update Posted: May 1, 2019
Last Verified: April 2019
Keywords provided by Wales Cancer Trials Unit:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Mesothelial
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action